Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma

Journal of Pathology

Volumn 190, Issue 4, 2000, Pages 457-461

  Schraml, P ^a   Muller D ^a   Bednar, R ^a   Gasser, Th ^a   Sauter, G ^a   Mihatsch, M J ^a   Moch, H ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Chromosome 9p; LOH; Molecular genetics; p16; Papillary renal cell carcinoma

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 9P; CHROMOSOME DELETION; CLINICAL FEATURE; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 9; HUMANS; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0343674751     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200003)190:4<457::AID-PATH551>3.0.CO;2-C     Document Type: Article

References (40)

1. Kovacs G, Akhtar M, Beckwith B, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183: 131-133.
2. Bostwick D, Eble J, Denis L, Murphy G, von Eschenbach A. Diagnosis and prognosis of renal cell carcinoma. Cancer 1997; 80: 973-1001.
3. Amin M, Corless C, Renshaaw A, Tickoo S, Kubus J, Schultz D. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 1997; 21: 621-635.
4. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 1987; 327: 721-727.
5. Presti J, Rao H, Chen Q, et al. Histopathological, cytogenetic, and molecular characterization of renal cortical tumours. Cancer Res 1991; 51: 1544-1552.
6. Kovacs G. Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am J Pathol 1989; 134: 27-34.
7. Presti J, Reuter V, Cordon-Cardo C, Mazumdar M, Fair W, Jhanwar S. Allelic deletions in renal tumours: histopathological correlations. Cancer Res 1993; 53: 5780-5783.
8. Moch H, Presti JC Jr, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 1996; 56: 27-30.
9. Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol 1997; 183: 151-155.
10. van den Berg E, van der Hout AH, Oosterhuis JW, et al. Cytogenetic analysis of epithelial renal-cell tumours: relationship with a new histopathological classification. Int J Cancer 1993; 55: 223-227.
11. Kinoshita H, Yamada H, Ogawa O, et al. Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma. Jpn J Cancer Res 1995; 86: 795-799.
12. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumours with 9p loss. Science 1994; 265: 415-417.
13. Cairns P, Shaw M, Knowles M. Initiation of bladder cancer may involve deletions of a tumour-suppressor gene on chromosome 9. Oncogene 1993; 8: 1083-1085.
14. Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumour suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 1995; 55: 224-227.
15. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet 1995; 11: 210-212.
16. Thrash Bingham CA, Greenberg RE, Howard S, et al. Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad Sci U S A 1995; 92: 2854-2858.
17. Thrash-Bingham CA, Salazar H, Freed JJ, Greenberg RE, Tartof KD. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumour pathology. Cancer Res 1995; 55: 6189-6195.
18. Thoenes W, Stoerkel S, Rumpelt H. Histopathology and classification of renal cell tumours (adenomas, oncocytomas, and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986; 181: 125-143.
19. Moch H, Schraml P, Bubendorf L, et al. Intratumoral heterogeneity of 3p deletions in renal cell carcinoma detected by fluorescence in situ hybridization. Cancer Res 1998; 58: 2304-2309.
20. Kovacs G. Molecular differential pathology of renal tumours. Histopathology 1993; 22: 1-8.
21. Bugert P, Kovacs G. Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol 1996; 149: 2081-2088.
22. Jiang F, Richter J, Schraml P, et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histologic subtypes. Am J Pathol 1998; 153: 1467-1473.
23. Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 1992; 89: 10557-10561.
24. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994; 8: 23-26.
25. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-756.
26. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest [see comments]. Nature 1994; 371: 257-261.
27. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumour suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
28. Mao L, Merlo A, Bedi G, et al. A novel p16INK4A transcript. Cancer Res 1995; 55: 2995-2997.
29. Merlo A, Gabrielson E, Askin F, Sidransky D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res 1994; 54: 640-642.
30. Lydiatt WM, Davidson BJ, Schantz SP, Caruana S, Chaganti RS. 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck 1998; 20: 113-118.
31. Maruno M, Yoshimine T, Muhammad AK, Tokiyoshi K, Hayakawa T. Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumours and its prognostic implications. J Neurooncol 1996; 30: 19-24.
32. An HX, Niederacher D, Picard F, van Roeyen C, Bender HG, Beckmann MW. Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. Genes Chromosomes Cancer 1996; 17: 14-20.
33. Tarmin L, Yin J, Zhou X, et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res 1994; 54: 6094-6096.
34. Ohta M, Berd D, Shimizu M, et al. Deletion mapping of chromosome region 9p21 p22 surrounding the CDKN2 locus in melanoma. Int J Cancer 1996; 65: 762-767.
35. Cheng JQ, Jhanwar SC, Lu YY, Testa JR. Homozygous deletions within 9p21 p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 1993; 53: 4761-4763.
36. Marshall B, Isidro G, Martins AG, Boavida MG. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions. Cancer Genet Cytogenet 1997; 96: 134-139.
37. Takita J, Hayashi Y, Kohno T, et al. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuro-blastoma. Cancer Res 1997; 57: 907-912.
38. Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, Clayton RN. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res 1997; 57: 2703-2709.
39. Takeuchi S, Koike M, Seriu T, et al. Homozygous deletions at 9p21 in childhood acute lymphoblastic leukemia detected by microsatellite analysis. Leukemia 1997; 11: 1636-1640.
40. Lothe R. Microsatellite instability in human solid tumours. Mol Med 1997; 3: 61-68.